glp 1 agonist microdosing GLP-1 People Are Microdosing Weight-Loss Drugs
Description
It is closely linked to social deprivation, with the highest rates found in some of the most disadvantaged areas
Key takeaways Health insurance companies may stop covering GLP-1 medications for weight loss due to their rising costs and questions about their necessity
Eli Lillys GLP-1 offering, tirzepatide, launched shortly after (as Mounjaro for T2D in 2022 and Zepbound for obesity in 2023), demonstrated greater HbA1c reduction and up to a 20% placebo-adjusted weight loss
Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al
Gray market sources are unregulated
In order to continue receiving Zepbound coverage, you may also need to prove youve lost a certain amount of weight while using the drug
